Answers to common questions about COVID-19 vaccines in children with cancer

Miguela A. Caniza1,2,3 | Maysam R. Homsi1 | Jessica Bate4 | Riyadi Adrizain5 | Tarek Ahmed6 | Sarah Alexander7 | Arpita Bhattacharyya8 | Jose Luis Copado-Gutierrez9 | Ivan Gutierrez10,11 | Yan Yin Lim12 | Lisa Morrissey13 | Gita Naidu14 | Vivian Paintsil15 | Nita Radhakrishnan16 | Sheena Mukkada1,2 | Robert Phillips17,18 | Kenneth A. Alexander19 | Kathy Pritchard-Jones20

1Departments of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
2Departments of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
3Department of or Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA
4Department of Paediatric Oncology, Southampton Children’s Hospital, Southampton, UK
5Department of Child Health, Faculty of Medicine Universitas Padjadjaran Dr. Hasan Sadikin General Hospital, Bandung, Indonesia
6Department of Pediatric Oncology, Children’s Cancer Hospital Egypt, Cairo, Egypt
7Division of Haematology/Oncology, Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada
8Department of Pediatric Oncology, Tata Medical Center, Kolkata, India
9Division of Health Sciences, Universidad Anahuac Queretaro, Queretaro, Mexico
10Department of Pediatric Infectious Diseases, Research Group Colsubsidio Investig, Clinical Infantil Colsubsidio, Bogotá, Colombia
11Division of Pediatric Infectious Diseases, Clinica Infantil Santa María del Lago, Bogotá, Colombia
12Division of Nursing, KK Women’s and Children’s Hospital, Singapore, Singapore
13Department of Nursing, Boston Children’s Hospital, Boston, Massachusetts, USA
14Department of Pediatric Oncology, Chris Han Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa
15Department of Child Health, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
16Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India
17Regional Department of Hematology and Oncology, Leeds Children’s Hospital, Leeds, UK
18Centre for Reviews and Dissemination, University of York, York, UK
19Department of Pediatrics, Division of Infectious Diseases, Nemours Children’s Hospital-Florida, Orlando, Florida, USA
20Developmental Biology and Cancer Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK

Correspondence
Miguela A. Caniza, Department of Global Pediatric Medicine, MS 721, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA.
Email: miguela.caniza@stjude.org

Abstract

Background: The SARS-CoV-2 outbreak in 2020 evolved into a global pandemic, and COVID-19 vaccines became rapidly available, including for pediatric patients. However, questions emerged that challenged vaccine acceptance and use. We aimed to answer these questions and give recommendations applicable for use in pediatric patients with cancer by healthcare professionals and the public.

Abbreviations: AAP, American Academy of Pediatrics; CAR, chimeric antigen receptor; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CLL, chronic lymphocytic leukemia; EUA, Emergency Use Authorization; US FDA, United States Food and Drug Administration; HCT, hematopoietic cell transplantation; HIC, high-income country; LIC, low-income country; LMIC, low-middle-income country; WHO, World Health Organization.
**Methods:** A 12-member global COVID-19 Vaccine in Pediatric Oncology Working Group made up of physicians and nurses from all world regions met weekly from March to July 2021. We used a modified Delphi method to select the top questions. The Working Group, in four-member subgroups, answered assigned questions by providing brief recommendations, followed by a discussion of the rationale for each answer. All Working Group members voted on each recommendation using a scale of 1 to 10, 10 being complete agreement. A “pass” recommendation corresponded to an agreement ≥7.5.

**Results:** We selected 15 questions from 173 suggested questions. Based on existing published information, we generated answers for each question as recommendations. The overall average agreement for the 24 recommendations was 9.5 (95% CI 9.4–9.6).

**Conclusion:** Top COVID-19 vaccine-related questions could be answered using available information. Reports on COVID-19 vaccination and related topics have been published at record speed, aided by available technology and the priority imposed by the pandemic; however, all efforts were made to incorporate emerging information throughout our project. Recommendations will be periodically updated on a dedicated website.

**KEYWORDS**
COVID-19, infectious diseases, infection prevention, pediatric cancer, vaccines

### 1 | INTRODUCTION

The SARS-CoV-2 outbreak in Wuhan, China, in late 2019, rapidly evolved into a global pandemic, and vaccines emerged, as expected, to effectively control the disease.\(^1\) Pharmaceutical companies quickly completed all steps for regulatory approval of several COVID-19 vaccines that were then made available to the public under the Emergency Use Authorization (EUA) of supervisory and regulatory agencies.\(^2\)–\(^5\) Despite compelling evidence indicating their effectiveness, multiple questions about the vaccines arose. These questions came from healthcare providers, patients, and families, including concerns about the safety of COVID-19 vaccines for children with cancer, hematopoietic cell transplant (HCT) or cellular therapy.

We aimed to review and select common, relevant questions about COVID-19 vaccines; answer those questions with the available evidence and information; and provide summary recommendations for healthcare providers, caregivers, and patients. Here, we share how we selected the questions and our method for answering them by summarizing the available scientific literature and expert opinions.

### 2 | METHODS

#### 2.1 | Working group selection

In March 2021, the multidisciplinary COVID-19 Vaccine in Pediatric Oncology Working Group was formed to answer emerging questions about the use of COVID-19 vaccines in children with cancer and/or HCT. The Working Group, composed of 12 individuals, including oncologists, infectious diseases physicians, and nurses from all World Health Organization (WHO) regions (Table 1), shared a global and multidisciplinary perspective. Members were nominated by the International Society of Pediatric Oncology regional leadership. Members were organized into four three-person subgroups, and consultants provided additional methodology and content expertise support. A parent/caregiver advisory group from around the world, established concurrently with our Working Group, has independently reported their findings of a survey of COVID-19 vaccine questions relevant to parents and caregivers.\(^6\)

#### 2.2 | Targeted audience

We targeted healthcare providers, patient caregivers, families, and patients who need information to guide their recommendations and decisions about COVID-19 vaccines. Healthcare institutions, organizations’ leaders, and decision makers for children with cancer, including families and healthcare providers, were also considered.

#### 2.3 | Virtual meetings and data management

Working Group coordinators and subgroup members held weekly meetings from March to July 2021 to communicate and discuss their progress. Project methods, including voting processes and
TABLE 1  Question assignments and Working Group members’ countries and specialties

| Question assignments | Members’ initials | Country (WHO regional groupings of countries) | Country economic classification | Specialty |
|----------------------|------------------|---------------------------------------------|--------------------------------|-----------|
| 1–3                  | AB               | India (SEAR)                                | X                               | PO        |
|                      | VP               | Ghana (AFR)                                 | X                               | PO        |
|                      | LM               | United States (AMR)                         |                                 |           |
| 4–6                  | JB               | United Kingdom (EUR)                        | X                               | PO        |
|                      | JLC              | Mexico (AMR)                                | X                               | PID       |
|                      | GN               | South Africa (AFR)                          | X                               | PO        |
| 7–11                 | NR               | India (SEAR)                                | X                               | PO        |
|                      | RA               | Indonesia (SEAR)                            | X                               | PID       |
|                      | SA               | Canada (AMR)                                |                                 |           |
| 12–15                | TA               | Egypt (EMR)                                 | X                               | PO        |
|                      | IG               | Colombia (AMR)                              | X                               | PID       |
|                      | YYL              | Singapore (WPR)                             | X                               | N         |

Abbreviations: AFR, African region; AMR, American region; EMR, Eastern Mediterranean region; EUR, European region; N, nursing; PID, pediatric infectious diseases; PO, pediatric oncology; SEAR, South-East Asian Pacific region; WHO, World Health Organization; WPR, Western Pacific region.

2.4  Question selection

Questions about COVID-19 vaccines from professional healthcare organizations’ websites were reviewed. These websites were the American Cancer Society; Cancer Connect; Centers of Disease Control and Prevention (CDC); Fred Hutchinson Cancer Research Center; MD Anderson Cancer Center; The National Academies of Sciences, Engineering, and Medicine; Pancreatic Cancer Action Network; Tennessee Department of Health; St. Jude Children’s Research Hospital; and the WHO. After collating 173 questions, we employed a modified Delphi method to identify the most relevant ones for our target audience (Figure 1). The list of questions was prepared through an electronic survey platform and distributed to 12 voting members to determine the importance of each question by using a Likert Scale (1 = not at all important, 5 = extremely important). Members also had the option to vote “0 = Beyond the scope” for questions unrelated to vaccinating children with cancer. Finally, Working Group members contributed to the list of questions for the panel to vote on during succeeding rounds. All voting was conducted anonymously.

Three voting sessions, as collective decision venues of the Working Group, were organized to select the top questions. Each panelist received a link to the electronic survey platform. In the first round, the panelists ranked an initial list of 132 questions selected from professional healthcare organizations’ websites. After this initial vote, 30 top-scoring questions and 37 additional questions proposed by the subgroups were combined for the next round of voting. These added questions reflected the members’ professional medical experiences, and the panel ranked the 67 questions during the second round of voting. The rankings were shared at a virtual meeting and displayed using the digital online whiteboard platform (MURAL® [https://www.mural.co/]). Over the subsequent two sessions, the panel completed the third round of voting through open discussion until a consensus was reached on the 15 most essential questions (Q1–Q15) to answer (Table 2 and Figure 1).

2.5  Literature review

The search strategy was developed in collaboration with the St. Jude Biomedical Library. For the search in PubMed, a combination of keywords, medical subject headings terms, and filters was used. Because of the rapidly evolving evidence base for SARS-CoV-2, new publications that became available after the search strategy was completed were included in the review of evidence by members.

2.6  Review of the evidence

Each subgroup had three members, at least one of whom was an infectious diseases specialist or had training in infectious diseases. They prepared recommendations (R1–R15) for three to five questions by evaluating the citations generated by the search for relevance and study quality. Quality was assessed using the Oxford Levels of Evidence method, chosen for its relatively simple application and transparency.
### TABLE 2  Most relevant and frequent COVID-19 vaccine questions selected by the panel

| NUMBER | Question                                                                                                                                  |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | Is the vaccine safe for pediatric patients with cancer and other underlying immunocompromising conditions?                                  |
| 2      | What are the indications and contraindications for receiving the COVID-19 vaccine?                                                          |
| 3      | What considerations should be made for vaccinating patients during anticancer treatment? Does receiving the COVID-19 vaccine require altering anticancer treatment? |
| 4      | After anticancer treatment has been completed, is COVID-19 revaccination required if the patient was vaccinated while immunosuppressed?          |
| 5      | After bone marrow transplantation, when should the child receive a COVID-19 vaccine?                                                        |
| 6      | What is the recommendation for COVID-19 vaccination for children younger than 16 years of age, including infants?                            |
| 7      | Can children with cancer receive a COVID-19 vaccine if they are participating in a clinical trial?                                        |
| 8      | What are the findings of clinical trials testing the COVID-19 vaccine in the pediatric population?                                        |
| 9      | Which COVID-19 vaccines are approved for use in immunocompromised patients? Does it matter which type of vaccine they receive?                |
| 10     | Should caregivers and family members of patients with cancer receive the COVID-19 vaccine?                                                |
| 11     | Is it safe for patients with cancer who have received the COVID-19 vaccine to go back to school?                                          |
| 12     | What can healthcare providers do to address vaccine hesitancy?                                                                           |
| 13     | Should a previously infected patient (whether asymptomatic or symptomatic) receive a COVID-19 vaccine? How soon after SARS-CoV-2 infection should the patient receive the vaccine? |
| 14     | What is known about the long-term protection provided by the currently available COVID-19 vaccines?                                         |
| 15     | Can a vaccinated person still transmit COVID-19?                                                                                           |

### 2.7 Agreement with the recommendations

Each question, answer, and rationale were presented and discussed at Working Group meetings. Each member anonymously graded the recommendations on a 10-point Likert Scale (0 = complete disagreement, 5 = neutral position, 10 = complete agreement). The level of agreement for each recommendation was represented by the mean score and 95% confidence interval (CI).

### 2.8 Statistical analyses

To summarize the demographics of the Working Group, we used descriptive statistics; this included members’ medical specialty and the World Bank designations of their countries: high-income countries (HIC), upper-middle-income countries (UMIC), lower-middle-income countries (LMIC), and low-income countries (LIC) (Table 1). An average Likert score $\geq 7.5$ corresponded to a “pass” recommendation and was considered an agreement. We provided a mean score and 95% CI for each recommendation. CIs were constructed using a bias-correct bootstrap method with 5000 iterations per estimate and R software.

### 3 RESULTS

Q1. Is the vaccine safe for pediatric patients with cancer and other underlying immunocompromising conditions?

R1: The vaccine appears to be safe for patients with cancer and other underlying immunocompromising conditions.

Level of agreement: 9.4 (95% CI 9–9.8).

Q2. What are the indications and contraindications for receiving the COVID-19 vaccine?

R2a: Indications for receiving a COVID-19 vaccine include any individual with cancer undergoing treatment, any patient whose anticancer treatment has ended, and any patient who is at least 100 days post-HCT and chimeric antigen receptor (CAR) T-cell therapy.

Level of agreement: 9.2 (95% CI 8.5–9.8).

R2b: Contraindications for receiving a COVID-19 vaccine include any individual with a history of allergy to vaccine components, or any individual with a history of an anaphylactic reaction following the first dose of a COVID-19 vaccine. Vaccine may consist of mRNA, protein antigens, replication-defective adenovirus, toxoids, stabilizers, adjuvants, antibiotics, and preservatives.

Level of agreement: 9.8 (95% CI 8.6–10).

R2c: Those living in the same household as a person with cancer, caregiver, and close contacts should be vaccinated as soon as possible.

Level of agreement: 10 (95% CI 10–10).

Q3. What considerations should be made for vaccinating patients during anticancer treatment? Does receiving the COVID-19 vaccine require altering anticancer treatment?

R3a: If possible, COVID-19 vaccination should be completed at least 14 days before starting cancer-directed therapy.

Level of agreement: 9.4 (95% CI 8.9–9.8).
R3b: If anticancer therapy cannot be delayed, COVID-19 vaccination should be given outside of the period of anticipated anticancer therapy-induced cytopenia.
Level of agreement: 9.4 (95% CI 8.6–9.9).
R3c: For recipients of HCT and CAR T-cell therapy, COVID-19 vaccination is recommended a minimum of 100 days after completion of transplantation therapy.
Level of agreement: 9.2 (95% CI 8.7–9.7).
R3d: There is no indication for altering anticancer treatment after COVID-19 vaccination.
Level of agreement: 9.6 (95% CI 9.2–9.9).
Q4. After anticancer treatment has been completed, is COVID-19 revaccination required if the patient was vaccinated while immunosuppressed?
R4a: An additional dose is indicated for the primary vaccine series to increase the immune response in patients who received BNT162b2 mRNA or mRNA-1273 SARS-CoV-2 vaccines.
Level of agreement: 8.8 (95% CI 7.9–9.5).
R4b: A booster dose is indicated to enhance or reestablish the protection by the primary series of COVID-19 vaccine doses.
Level of agreement: 9.5 (95% CI 9–9.9).
Q5. After bone marrow transplantation, when should the child receive a COVID-19 vaccine?
R5a: Current recommendations by leading international professional organizations support vaccinating patients as early as 100 days after HCT and CAR T-cell therapy.
Level of agreement: 9.3 (95% CI 8.5–9.9).
R5b: Patients who received COVID-19 vaccination prior to HCT should be revaccinated with a complete COVID-19 vaccine series at least 100 days after HCT and CAR T-cell therapy.
Level of agreement: 9.4 (95% CI 8.7–9.9).
Q6. What is the recommendation for COVID-19 vaccination for children younger than 16 years of age, including infants?
R6a: All children (≥5 years), including those with cancer and receiving anticancer treatment or who recently completed anticancer treatment, should be vaccinated against COVID-19 by using an approved dosage for the age group.
Level of agreement: 9.3 (95% CI 8.6–9.8).
R6b: All survivors of childhood cancer should be vaccinated.
Level of agreement: 9.8 (95% CI 9.5–10).
R6c: All children (≥5 years) with certain nonmalignant hematologic disorders (e.g., aplastic anemia, sickle cell disease, Evans syndrome, Schwachman diamond syndrome, Fanconi anemia) should be vaccinated with an approved dosage for the age group.
Level of agreement: 9.4 (95% CI 8.7–9.9).
Q7. Can children with cancer receive a COVID-19 vaccine if they are participating in a clinical trial?
R7: The decision to administer a COVID-19 vaccine to a pediatric patient participating in a therapeutic clinical trial must be based on the individual patient, the underlying disease severity/stage of progression, and the criteria of the clinical trial in which the child is enrolled.
Level of agreement: 9.2 (95% CI 8.4–9.9).
Q8. What are the findings of clinical trials testing the COVID-19 vaccine in the pediatric population?
R8: The BNT162b2 vaccine is safe and effective in children 5 years or older.
Level of agreement: 9.1 (95% CI 8.2–9.8).
Q9. Which COVID-19 vaccines are approved for use in immunocompromised patients? Does it matter which type of vaccine they receive?
R9: Patients should receive the COVID-19 vaccine for which they are eligible and have access. However, live-attenuated virus vaccines and replicating viral-vectored vaccines are not recommended for patients with immunosuppression.
Level of agreement: 9.8 (95% CI 9.5–10).
Q10. Should caregivers and family members of patients with cancer receive the COVID-19 vaccine?
R10: Caregivers, family members, close contacts, and household members of patients with cancer should be vaccinated against COVID-19.
Level of agreement: 10 (95% CI 10–10).

Q11. Is it safe for patients with cancer who have received the COVID-19 vaccine to go back to school?

R10: In-person school attendance for children receiving anticancer therapy during the COVID-19 pandemic requires individualized decision-making; however, vaccination should be considered.

Level of agreement: 9.1 (95% CI 8.3–9.8).

Q12. What can healthcare providers do to address vaccine hesitancy?

R12: Healthcare providers should initiate conversations with caregivers and family members of patients with cancer at an early stage to understand and address their underlying concerns about getting vaccinated against COVID-19 and promote vaccination acceptability.

Level of agreement: 9.8 (95% CI 9.5–10).

Q13. Should a previously infected patient (asymptomatic or symptomatic) receive a COVID-19 vaccine? How soon after SARS-CoV-2 infection should the patient receive the vaccine?

R13: Children with a history of SARS-CoV-2 infection should be offered vaccination whenever feasible. Children can safely wait for 2–3 months after infection before getting vaccinated.

Level of agreement: 9.3 (95% CI 8.7–9.8).

Q14. What is known about the long-term protection provided by the currently available COVID-19 vaccines?

R14: COVID-19 vaccines do not provide lifelong protective antibody levels; the antibody level wanes after several months, requiring a COVID-19 vaccine booster dose to maintain a protective level of immunity.

Level of agreement: 9.6 (95% CI 8.9–10).

Q15. Can a vaccinated person still transmit COVID-19?

R15: Fully vaccinated people can experience a breakthrough infection and transmit COVID-19 to others.

Level of agreement: 9.8 (95% CI 9.4–10).

4 I DISCUSSION

A Working Group, representing healthcare workers of children with cancer from all world regions, identified and selected 15 questions about COVID-19 vaccines in children with cancer and HCT. Questions addressed the safety and efficacy of COVID-19 vaccines for the pediatric population, including those with cancer; COVID-19 vaccines indications and contraindications in relation to the treatment of cancer and HCT; vaccination for care providers and family members to protect the patient with cancer; and patient protection when attending schools. Finally, questions about COVID-19 vaccination hesitancy were also identified.

Safety information about COVID-19 vaccines in pediatric patients with active cancer or receiving anticancer treatment was extrapolated from data obtained from adult patients and immunocompetent children.10–12 None of the current COVID-19 vaccines are "live" vaccines (Table 3), which is important because vaccines that contain agents that actively replicate in the recipient should be avoided in immunocompromised individuals, including patients with malignancies undergoing treatment.13 Despite a milder manifestation of COVID-19 among children,14 the severity in selected pediatric populations of some ethnic backgrounds, low socioeconomic status,15 or those with comorbidities16 was unacceptable. Among children with cancer, the severity of COVID-19 was associated with age older than 11 years, pulmonary comorbidities, obesity, cytopenia, and certain malignancies.17 As efficacy data became available,11,12 public health and global health agencies and professional organizations have recommended pediatric vaccination.18–20 Multiple COVID-19 vaccines are currently available, but for children and adolescents, the efficacy and safety data are available only for BNT162b211,12 and mRNA-1273.21,22 Clinical trials in adolescents (12–17 years old)11 and children (5–11 years old)12 showed that BNT162b2 is safe, immunogenic, and efficacious. Similarly, clinical trials of mRNA-1273 vaccine among adolescents22 and children21 demonstrated safety and efficacy. Both vaccines are currently indicated for these age groups in many regions of the world.19,23–25 Small myocarditis risk documented in children and adolescent outweighs the benefit of COVID-19 vaccine.26,27 Although the safety should be similar in age-matched children with cancer, vaccine efficacy will likely be lower in immunocompromised children. The best information would be gained by a clinical trial of COVID-19 vaccination in children with cancer. Until such trial is conducted, a surveillance of the safety and immunogenicity of vaccine administered to any child or adolescent, especially those with cancer, could provide valuable information. In agreement with Hwang et al.,28 we advocate creating national reporting systems for pediatric patients receiving anticancer treatment and COVID-19 vaccines. Such reports would facilitate safety, immunogenicity, and efficacy studies of patients with cancer.

Although the immune response to vaccination in patients with cancer may be lower than that of healthy individuals, vaccination may still prevent or decrease the severity of infections, including in those with specific medical conditions (Figure 2). Thus, public health agencies and professional societies broadly recommend vaccination, including for children with cancer and those receiving HCT/cellular therapy.29–35 The recommendations of the National Cancer Institute and the CDC are that all patients with cancer receive a COVID-19 vaccine.36,37 Those who have undergone HCT or received CAR T-cell therapy should delay the COVID-19 vaccine until 100 days after completion of treatment.36 A systematic review37 of patients with solid tumors in remission, myeloproliferative neoplasia, myelodysplastic syndromes without treatment, and those receiving endocrine treatment or noncytotoxic drugs showed no restrictions or time window for vaccination. However, for patients with lymphoid malignancies requiring B-cell-depleting agents and those with solid tumors requiring cytotoxic agents, COVID-19 vaccines should be given before the planned anticancer regimen, if feasible. If not, vaccine doses should be timed to avoid coinciding with expected chemotherapy-induced cytopenia. Anti-CD20 antibody therapy produces a blunted immune response to vaccines, including a COVID-19 vaccine, especially in those patients on active treatment (less than 3 months after receiving anticancer therapy).38 The preexposure prophylaxis product tixagevimab copackaged with cagivimab received EUA approval for situations in...
**TABLE 3** Information about COVID-19 vaccines

| Vaccine name                        | Platform             | Manufacturer/location                      | Minimum age | No. doses for primary series |
|-------------------------------------|----------------------|--------------------------------------------|-------------|------------------------------|
| BNT162b2 (COMIRNATY)                | mRNA                 | Pfizer and BioNTech/USA                    | 6 months    | 3 (6 months–4 years) 2 (≥5 years) |
| mRNA-1273 SPIKEVAX                  | mRNA                 | Moderna/USA                                 | 6 months    | 2                            |
| NVX-CoV2373 Novavax                 | Adjuvanted SARS-CoV-2 recombinant spike protein | Novavax/USA                                | 18 years    | 2                            |
| AZD1222 Vaxzevria                   | Nonreplicating chimp adenovirus-vector encoding the spike protein gene of SARS-CoV-2 | SK BIO Oxford-AstraZeneca/UK               | 18 years    | 2                            |
| Sinopharm/BIBP COVID-19 vaccine     | Inactivated SARS-CoV-2 | Beijing Institute of Biological Products Co., Ltd./China | 18 years    | 2                            |
| Sinopharm (Wuhan)                   | Inactivated SARS-CoV-2 | Sinopharm's Wuhan Institute of Biological Products/China | 18 years    | 2                            |
| CoronaVac                           | Inactivated SARS-CoV-2 | Sinovac Biotec/China                        | 18 years    | 2                            |
| BBV152 Covaxin                      | Inactivated SARS-CoV-2 | Bharat Biotech and Indian Council of Medical Research/India | 18 years    | 2                            |
| Ad26.COV2.Sβ                        | Replication-incompetent recombinant adenovirus serotype 26, vector for SARS-CoV-2 spike protein gene | Janssen (Johnson & Johnson)/USA            | 18 years    | 1                            |
| Sputnik V                           | Human nonreplicative Ad26 (in first dose) and Ad5 (in second dose) adenovirus vector modified for SARS-CoV-2 spike protein gene | The Gamaleya Research Institute of Epidemiology and Microbiology/Russia | 18 years    | 2                            |
| Sputnik Light                       | Nonreplicating recombinant adenovirus Ad26 vector for spike protein gene of SARS-CoV-2 | The Gamaleya Research Institute of Epidemiology and Microbiology/Russia | 18 years    | 1                            |
| Soberana 2                          | Recombinant SARS-CoV-2 receptor-binding domain–conjugated to tetanus toxoid | The Finlay Vaccine Institute and The Centre of Molecular Immunology/Cuba | 19 years    | 2                            |
| Soberana Plus<sup>c</sup>           | Dimeric SARS-CoV-2 receptor-binding domain adsorbed on 1250-µg alumina | The Finlay Vaccine Institute and The Centre of Molecular Immunology/Cuba | 19 years    | 1                            |

<sup>a</sup>The information presented here was extracted from: Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process. <sup>76</sup><br><sup>b</sup>CVID-19 vaccines approved or authorized by the US FDA under EUA (06/27/2022). <sup>30</sup><br><sup>c</sup>Soberana Plus vaccine is administered as a booster for individuals with preexisting immunity to SARS-CoV-2.

which COVID-19 vaccination might not be effective or persons may experience severe reaction to the COVID-19 vaccines. <sup>39</sup> Knowledge of vaccine components can guide selection of alternative products for those who exhibit an allergic reaction. <sup>18</sup>

Children receiving chemotherapy have lower seroconversion and seroprotection rates after vaccination than do healthy children. <sup>40</sup> The rate of COVID-19 vaccine seroconversion in adult patients with cancer is lower than that in immunocompetent patients. <sup>37</sup> Similarly, seroconversion rates are low in patients with hematologic malignancies and patients receiving highly immunosuppressive therapies and HCT. <sup>10</sup> The level of immunity achieved depends on the underlying diagnosis, the intensity of chemotherapy received, the timing of treatment, and any preexisting immune dysfunction. <sup>10,37</sup> Higher or additional vaccine doses <sup>41,42</sup> are frequently used when immunizing oncology patients against influenza. An additional dose of vaccine is recommended for immunosuppressed patients, if they were vaccinated while immunosuppressed (Table 4). <sup>29–31,33</sup> This additional COVID-19 vaccine dose is expected to maximize protection. Surveillance of children with cancer receiving COVID-19 vaccines should assess the duration of immune response to ascertain the frequency of booster doses required to extend protection. Data from COVID-19 vaccine studies in adults indicate waning immunity over time. <sup>43,44</sup> Experience and relevant data suggest that immunization could be started 6–12 months after HCT and CAR T-cell therapies. <sup>13</sup> Surveillance data suggest that COVID-19 vaccination of patients post-HCT can mount a preliminary immune response to COVID-19 and other vaccinations and that vaccination should begin 3 months after transplantation. <sup>55,46</sup> Based on these data, professional societies...
| Vaccine     | Age indication | Primary dose\(^b\) | No. of doses in PS | Interval between doses | Additional dose for immunocompromised people | BD recommendation and interval between previous dose 1st BD | BD recommendation and interval between 1st BD 2nd BD |
|-------------|----------------|--------------------|--------------------|------------------------|-----------------------------------------------|----------------------------------------------------------|--------------------------------------------------|
| BNT162b2    | 6 mos–4 y      | 3                  | 3                  | 3 wks between dose 1 and dose 2 ≥ 8 wks between dose 2 and dose 3 | NR                                            | BD NR                                                   | BD NR                                            |
| BNT162b2    | 5–11 y         | 10                 | 2                  | 3 wks (21 days)        | Recommended (≥ 28 days)                       | BD recommended ≥ 3 months for immunocompromised (If primary is BNT162b2) | BD NR                                            |
| BNT162b2    | 12–17 y        | 30                 | 2                  | 3 wks (21 days)        | Recommended (≥ 28 days)                       | BD recommended ≥ 3 months for immunocompromised (If primary is BNT162b2) | BD recommended ≥ 4 months for immunocompromised (If primary is BNT162b2) |
| BNT162b2    | ≥ 18 y          | 30                 | 2                  | 3 wks (21 days)        | Recommended (≥ 28 days)                       | BD recommended ≥ 3 months for immunocompromised (If primary is BNT162b2) | BD recommended ≥ 4 months for immunocompromised (If primary is BNT162b2) |
| mRNA-1273   | 6 mos–5 y      | 25                 | 2                  | 1 month (28 days)      | Recommended (≥ 28 days)                       | BD NR                                                   | BD NR                                            |
| mRNA-1273   | 6–11 y         | 50                 | 2                  | 1 month (28 days)      | Recommended (≥ 28 days)                       | BD NR                                                   | BD NR                                            |
| mRNA-1273   | 12–17 y        | 100                | 2                  | 1 month (28 days)      | Recommended (≥ 28 days)                       | BD NR                                                   | BD NR                                            |
| mRNA-1273   | ≥ 18 y          | 100                | 2                  | 1 month (28 days)      | Recommended (≥ 28 days)                       | BD recommended ≥ 3 months for immunocompromised (If primary is mRNA-1273; BD 50 µg) | BD recommended ≥ 4 months for immunocompromised (If primary is mRNA-1273; BD 50 µg) |
| Ad26.COVID2.5 | ≥ 18 y    | 5 × 1010 viral particles | 1                  | N/A                    | Recommended (≥ 28 days)                       | Recommended mRNA vaccine dose ≥ 2 months (If primary is J&J/Janssen) | BD recommended mRNA vaccine dose ≥ 4 months for immunocompromised (If primary is Ad26.COVID2.5) |
| NVX-CoV2373 | ≥ 18 y          | 5                  | 2                  | 3–8 wks (3 wks in immunocompromised) | NR                                            | BD NR                                                   | BD NR                                            |

\(^a\)The information presented here was extracted from COVID-19 Vaccines for Moderately to Severely Immunocompromised People.\(^30\)

\(^b\)The primary dose of vaccine is given in micrograms, unless otherwise indicated.

Abbreviations: BD, booster dose; J&J, Johnson & Johnson; N/A, not applicable; NR, not recommended; PS, primary schedule; wks, weeks; y, years.

Note: BNT162b2 product is the Pfizer-BioNTech or COMIRNATY® vaccine; mRNA-1273 product is the SPIKEVAX or Moderna; and the Ad26.COVID2.5 product is the Janssen vaccine. NVX-CoV2373 product is the Novavax.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-moderna-pfizer-children-vaccine-etr.html
Immunosuppressive states (humoral and cellular). These states can occur during cancer, organ transplantation, HCT and CAR T–cell therapies, and HIV infection. Situations applying to children with hematologic and/or oncologic disease are listed below (the list is not exhaustive).

- **Severe**: Primary or inherited immunodeficiencies, such as X-linked agammaglobulinemia, SCID, and CGD; secondary or acquired immunodeficiency caused by a disease process or its therapy, such as HCT (<100 days post-HCT and ALC <100 or severe GvHD), ALL on induction with ALC <100, recent T-cell therapy (ATG <90 days, alemtuzumab <6 months); HIV with CD4+ T-cell count <100.
- **Moderate**: ALL on induction with ALC 100-300; other malignancies with ALC <100; bone marrow failure with ALC <100; other high doses of immunosuppressant (example steroids); HIV infection with CD4+ T-cell count 100-200.

- Sickle cell disease or thalassemia
- Chronic organ diseases: kidney disease, liver disease, lung disease, heart disease
- Cystic fibrosis
- Neurologic disease
- Type 1 or 2 diabetes
- Down syndrome
- Obesity
- Tuberculosis

*A COVID-19 infection is considered severe when a person with COVID-19 is hospitalized, needs intensive care, requires a ventilator for breathing, and/or dies from COVID-19.*

**Abbreviations**: ALC, absolute lymphocyte count; ALL, acute lymphoblastic leukemia; ATG, anti–thymocyte globulin; CAR, chimeric antigen receptor; CGD, chronic granulomatous disease; GvHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; SCID, severe combined immunodeficiency disease

**FIGURE 2** Medical conditions that can result in severe COVID-19

recommend vaccinating patients as early as 100 days post-HCT and CAR T-cell therapy. The efficacy of primary vaccination and boosters regimen in immunocompromised patients should be studied and reported. These additional doses and booster indications include those with HCT and CAR T-cell therapy. Moreover, like influenza, the SARS-CoV-2 transmission rate in the community and the emergence of new variants should be considered when deciding on additional vaccine composition and doses for any individual. COVID-19 vaccines are considered investigational agents and their use could complicate clinical trial eligibility or vaccine administration for an enrolled participant, if the protocol prohibits the concomitant use of other investigational agents. To address this, the United States Food and Drug Administration (US FDA) clarified that COVID-19 vaccines should not be considered investigational agents for patients in cancer clinical trials. The European Medicines Agency, and other organizations have provided guidance for using COVID-19 vaccines in cancer therapy trials.

Decisions about school attendance for children with cancer, regardless of the COVID-19 pandemic, are complex. Medical recommendations vary widely by geography, the type and phase of therapy, and parental choice. Even within the same oncology program, providers may offer varied guidance. Regardless of the vaccination status, children with cancer should adhere to local COVID-19-related public measures for school safety. Decisions about in-person school attendance could be guided by local, ongoing COVID-19 epidemiology and family preferences. During anticancer treatment, attending school in person might not increase the risk of infections if the patient adheres to immunization recommendations (e.g., influenza and COVID-19), uses respiratory barrier precautions (e.g., masks), and practices heightened hand hygiene. Factors that could inform and influence the decision to attend school include the patient’s age, the grade in which the patient is enrolled, vaccination against COVID-19 and other viruses (e.g., influenza), and the child’s medical condition and treatment plans. Adolescents attending high school may prefer returning to school if their stage of disease permits. In contrast, parents of younger children may opt to withhold in-person schooling for a limited period. Currently, professional organizations and agencies, including the WHO and the American Academy of Pediatrics (AAP) endorse in-person school attendance. To render school attendance safe during the COVID-19 pandemic, the AAP recommends that all eligible individuals, including children with cancer, receive COVID-19 vaccine. Also, for the 2021–2022 school year, the AAP recommended that all school staff and students older than 2 years wear face masks at school, regardless of vaccination status, especially during indoor activities. Furthermore, schools should follow local public health agencies’ guidelines for quarantine and isolation protocols. COVID-19
transmission rates in local schools should be reviewed periodically, and that information should guide school policies (e.g., implementing virtual learning).20

The Advisory Committee on Immunization Practices and other guidelines recommend that close contacts of immunosuppressed patients receive all routine immunizations for vaccine-preventable communicable diseases.13 Household spread of COVID-19 infection is well documented, and a recent meta-analysis showed secondary infection rates to be 17% in households.55 Caregivers and household members have a unique opportunity to protect immunocompromised patients with cancer. Immunizing caregivers, so-called “cocoon vaccination,”56 58 is a highly effective strategy for children with cancer who are not able to be vaccinated and should include household members and other close contacts. The National Comprehensive Cancer Network and the American Cancer Society both recommend this approach. These entities support using any of the available US FDA- or EUA-approved vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S vaccine) in eligible patients.29,57

Acceptance rates of COVID-19 vaccination among parents and caregivers range from 52 to 89% across multiple studies.58–65 In congruence with the WHO vaccine-hesitancy model, the 3Cs,56 safety and efficacy of vaccine (Confidence), perceived lower risk of contracting and severity of disease among children (complacency), and vaccine literacy (convenience) were the major deterrents for families/caregivers in accepting COVID-19 vaccine for their child/children.58–65 67 No study has reported the effectiveness of interventions that address hesitancy for COVID-19 vaccination among the pediatric population. Communication remains an essential tool for the success of any immunization program.59,68 Open, transparent communication from trusted sources about the rationale for vaccination can significantly increase the confidence and uptake of vaccines. Healthcare providers are commonly described as the trusted source of information. Parents/caregivers are more likely to vaccinate their children if information and recommendations are given by their healthcare provider.58–61,69 Healthcare providers should use clear, comprehensible communication tailored to their audience’s literacy level, relevant to minority and underprivileged groups. Initiating conversations with parents/caregivers at an early stage to understand the underlying concerns about vaccine acceptability may allay anxiety and mitigate misinformation.59–61 Targeted educational efforts are required to clarify information about COVID-19 vaccination for parents or caregivers of a child with a chronic illness. Health communication messages should also emphasize the risk and consequences of the disease and the importance of COVID-19 vaccination for herd immunization, which could contribute to overall COVID-19 control.58,60,65,69 Training healthcare professionals to make recommendations using presumptive language and positive framing can increase vaccine acceptability among parents.70,71

5 | STUDY LIMITATIONS

COVID-19 is a new disease, and information about the disease, vaccination, and immune responses is evolving rapidly. Although efforts were maximized to include new information reported after the inception of our project and the best available evidence was applied to each answer, new findings have inevitably been published since manuscript preparation. Another potential limitation is that the websites used for selecting questions in Round 1 were primarily from North America. Nevertheless, more than half of the questions in the final 15-question list were provided by the global Working Group members. Early in the pandemic, a limited number of websites contained questions about COVID-19 vaccines, but more emerged as the pandemic unfolded. We reviewed two such websites31 32 and compared their questions with our 15-question list and found that we had addressed most questions on those sites.

6 | CONCLUSION

We identified 15 key COVID-19-related questions and answered them with the available information we carefully extracted from the growing body of literature. Similar recommendations to our study were reached by other professional associations, validating our findings.72,73 Reports addressing COVID-19 vaccines and related topics have been produced at record speed, aided by available technology and the priority imposed by the pandemic. As new information emerges, group members affiliated with professional networks, including the St. Jude Global Infectious Diseases Network, will continue to update recommendations on our dedicated website.74

AUTHOR CONTRIBUTIONS

M. A. C. designed the study, with additional input from M. R. H., J. B., K. A., and R. P. M. A. C. led the COVID-19 vaccine working group development, tasks distribution and actions monitoring, with the support of M. R. H. K. P. J. supported the recruitment of working group members from the International Society of Paediatric Oncology and provided study progress reviews. M. A. C. and M. R. H. oversaw data collection and analysis. All working group members (A. B., V. P., L. M., J. B., J. L. C., G. N., N. R., R. A., S. A., T. A., I. G., and Y. Y. L.) wrote their corresponding sections with input from M. A. C., M. R. H., K. A. A., R. P., and K. P. J.; S. M. provided additional input. All authors reviewed and approved the final manuscript. The corresponding author has full access to all the data and the final responsibility to submit for publication.

ACKNOWLEDGMENTS

This work was supported by ALSAC. We thank Angela McArthur, PhD, for excellent editorial support. Also, we thank Julie Edrington, MSIS, for library support. We thank an international parent/caregiver advisory group led by Jessica Bate, who studied the main questions from this group perspective.

CONFLICT OF INTEREST

The authors have no conflicts of interest relevant to this article to disclose.

ORCID

Miguela A. Caniza https://orcid.org/0000-0002-7846-9605

Maysam R. Homsi https://orcid.org/0000-0002-0665-246X
REFERENCES

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.

3. Walsh EE, French RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450.

4. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681.

5. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824-1835.

6. Gumy JM, Silverstein A, Kaye EC, et al. Global caregiver concerns of SARS-CoV-2 vaccination in children with cancer: a cross-sectional mixed-methods study. Pediatr Hematol Oncol. 2022:1-11.

7. Center for Evidence-Based Medicine: An introduction. 2021. Accessed December 8, 2021. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/levels-of-evidence-introductory-document

8. The World Bank. World Bank Country and Lending Groups. Country Classification. Accessed 29 March 2022. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Published 2022.

9. The R Development Team. The R Project for Statistical Computing. Accessed April 8, 2022. https://www.r-project.org/. Updated March 18, 2022.

10. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroscreening rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e1082.

11. French RW Jr., Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239-250.

12. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35-46.

13. Centers for Disease Control and Prevention. Altered Immunocompetence. General Best Practice Guidelines for Immunization: Best Practice Guidance of the Advisory Committee on Immunization Practices (ACIP). Accessed April 8, 2022. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html. Last reviewed March 15, 2022.

14. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-1242.

15. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCC): a cohort study. Lancet Oncol. 2021;22(10):1416-1426.

16. Graff K, Smith C, Silveira L, et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J. 2021;40(4):e137-e145.

17. Johnston EE, Martinez I, Davis ES, et al. SARS-CoV-2 in childhood cancer in 2020: a disease of disparities. J Clin Oncol. 2021;39(34):3778-3788.

18. Centers for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP. COVID-19. Accessed August 14, 2022. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html. Page last reviewed July 28, 2022.

19. Australian Government Department of Health and Aged Care. Approved COVID-19 vaccines. Accessed August 2, 2022. https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines. Updated 30 January 2022.

20. American Academy of Pediatrics. COVID-19 Guidance for Safe Schools and Promotion of In-Person Learning. Accessed August 14, 2022. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections клинического руководства по COVID-19-планированию-рассмотрения-возвращения-к-личному-образованию-в-школах. Updated July 6, 2022.

21. Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022;386(21):2011-2023.

22. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241-2251.

23. European Medicine Agency. COVID-19 vaccines: authorised. Accessed August 2, 2022. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19-covid-19-vaccines-authorised#authorised-covid-19-vaccines-section. Published 2022.

24. Government of Canada. Approved COVID-19 Vaccines. Accessed August 2, 2022. https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html. Published 2022.

25. Centers for Disease Control and Prevention. Use of COVID-19 vaccines in the United States: Interim Clinical Considerations. CDC. Accessed August 2, 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#booster-dose. Published 2021.

26. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977-982.

27. Morello R, Pepe M, Martino L, et al. COVID-19 review shows that benefits of vaccinating children and adolescents appear to outweigh risks of post-vaccination myocarditis. Acta Paediatr. 2022.

28. Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol. 2021;14(1):38.

29. American Society of Hematology. General Principles of COVID-19 Vaccines for Immunocompromised Patients. Accessed August 14, 2022. https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines. Updated April 14, 2022.

30. Centers for Disease Control and Prevention. COVID-19 Vaccines for Moderately to Severely Immunocompromised People. Accessed August 14, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. Updated July 20, 2022.

31. Children’s Cancer and Leukemia Group. COVID-19 guidance for children and young people with cancer undergoing treatment. Accessed August 14, 2022. https://www.cclg.org.uk/Coronavirus-advice. Updated 11 January 2022.

32. Royal College of Paediatrics and Child Health. COVID-19 vaccination for children and young people. Accessed August 14, 2022. https://www.rcpch.ac.uk/resources/covid-19-vaccination-children-young-people. Updated July 19, 2022.
33. National Cancer Institute. COVID-19: What People with Cancer Should Know. Accessed August 14, 2022. https://www.cancer.gov/about-cancer/coronavirus/coronavirus-cancer-patient-information. Updated July 21, 2022.
34. National Health Services. Health conditions and coronavirus (COVID-19) vaccination. Accessed August 14, 2022. https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination-health-conditions/. Last reviewed April 28, 2022.
35. American Cancer Society. COVID-19 Vaccines in People with Cancer. Accessed August 14, 2022. https://www.cancer.org/content/dam/CRC/PDF/Public/954700.pdf. Revised July 29, 2022.
36. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Accessed August 14, 2022. https://www.covid19treatmentguidelines.nih.gov/. Updated August 8, 2022.
37. Corti C, Antonarelli G, Scotte F, et al. Serocconversion rate after vaccination against COVID-19 in cancer patients-a systematic review. Ann Oncol. 2021.
38. Vignetha A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624-2643.
39. US Food and Drug Administration. Fact Sheet for Patients, Parents And Caregivers Emergency Use Authorization (EUA) of EVUSHIELD™ (tixagribivm co-packaged with cilgavibim) for Coronavirus Disease 2019 (COVID-19). Accessed August 1, 2022. https://www.fda.gov/media/154702/download.
40. Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect. 2012;18 Suppl 5:93-99.
41. Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66(11):1698-1704.
42. Mombelli M, Retby N, Perreau M, Pascual M, Pantaleo G, Manuel O. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: a randomized controlled trial. Vaccine. 2018;36(41):6163-6169.
43. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).
44. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259-2261.
45. Kumar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661-662.
46. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100.
47. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 vaccination on transmission of alpha and delta variants. N Engl J Med. 2022.
48. US Food and Drug Administration. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency. Guidance for Industry, Investigators, and Institutional Review Boards. Accessed April 8, 2022. https://www.fda.gov/media/136238/download. Updated August 30, 2021.
49. European Medical Agency. Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials. Accessed April 8, 2022. https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-imlications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical_en-0.pdf. Published 26 June 2020.
50. Desai A, Gainor JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313-319.
51. Simon A, Siebald, B, Stamm, W. School and kindergarten attendance and home schooling of pediatric cancer patients before and during the SARS-CoV-2 pandemic: results of a survey of the German Society for Pediatric Oncology and Hematology. GMS Hgy Infect Control. 2021;5.
52. World Health Organization. Considerations for school-related public health measures in the context of COVID-19. Accessed August 14, 2022. https://www.who.int/publications/i/item/considerations-for-school-related-public-health-measures-in-the-context-of-covid-19. Published September 2020.
53. af Sandeberg M, Wettergren L, Bjork O, Arvidsson J, Johansson E. Do school attendance during initial cancer treatment in childhood increase the risk of infection? Pediatr Blood Cancer. 2013;60(8):1307-1312.
54. American Academy of Pediatrics. American Academy of Pediatrics Updates Recommendations for Opening Schools in Fall 2021. Accessed August 13, 2022. https://www.aap.org/en-news-room/news-releases/aap/2021/american-academy-of-pediatrics-updates-recommendations-for-opening-schools-in-fall-2021/. Published 2021. Updated July 19, 2021.
55. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Network Open. 2020;3(12):e203175.
56. Woodfield MC, Pergam SA, Shah PD. Coconning against COVID-19: the argument for vaccinating caregivers of patients with cancer. Cancer. 2021;127(16):2861-2863.
57. National Comprehensive Cancer Network. COVID-19 Resources. Accessed August 14, 2022. https://www.nccn.org/covid-19. Published 2022.
58. Goldman RD, Yan TD, Seiler M, et al. Caregiver willingness to vaccinate their children against COVID-19: cross sectional survey. Vaccine. 2020;38(48):7668-7673.
59. Hudson A, Montelpare WJ. Predictors of vaccine hesitancy: implications for COVID-19 public health messaging. Int J Environ Res Public Health. 2021;18(15).
60. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. 2020;38(49):7789-7798.
61. Rhodes ME, Sundstrom B, Ritter E, McKeever BW, McKeever R. Preparing for a COVID-19 vaccine: a mixed methods study of vaccine hesitant parents. J Health Commun. 2020;25(10):831-837.
62. Skjette M, Ngirababul M, Akeju O, et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol. 2021;36(2):197-211.
63. Viswanath K, Bekalu M, Dhawan D, Pinnamani R, Lang J, McLeod R. Individual and social determinants of COVID-19 vaccine uptake. BMC Public Health. 2021;21(1):818.
64. Yigit M, Ozkaya-Parlakay A, Senel E. Evaluation of COVID-19 vaccine refusal in parents. Pediatr Infect Dis J. 2021;40(4):e134-e136.
65. Zhang KC, Fang Y, Cao H, et al. Parental acceptability of COVID-19 vaccination for children under the age of 18 years: cross-sectional online survey. JMIR Pediatr Parent. 2020;3(2):e24827.
66. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ, Hesitancy WSWGDwV. Hesitancy according to a survey over 5000 families from Bologna, Italy. Pediatr Infect Dis J. 2021;40(4):e134-e136.
67. Montalti M, Rallo F, Guaraldi F, et al. Would parents get their children vaccinated against SARS-CoV-2? Rate and predictors of vaccine hesitancy among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol. 2021;36(2):197-211.
68. Viswanath K, Bekalu M, Dhawan D, Pinnamani R, Lang J, McLeod R. Individual and social determinants of COVID-19 vaccine uptake. BMC Public Health. 2021;21(1):818.
71. Kelkar AH, Blake JA, Cherabuddi K, Cornett H, McKee BL, Cogle CR. Vaccine enthusiasm and hesitancy in cancer patients and the impact of a webinar. Healthcare (Basel). 2021;9(3).

72. Cesaro S, Muggeo P, Zama D, et al. Consensus on COVID-19 vaccination in pediatric oncohematological patients, on behalf of infectious working group of Italian Association of Pediatric Hematology Oncology. J Clin Med. 2022;11(5).

73. Furlong E, Kotecha RS, Conyers R, et al. COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology Oncology Group consensus statement. Med J Aust. 2022;216(6):312-319.

74. St Jude Global. COVID-19 and Childhood Cancer Vaccine Working Group. Accessed February 7, 2022. https://global.stjude.org/en-us/global-covid-19-observatory-and-resource-center-for-childhood-cancer/vaccine-working-group.html. Updated 2022.

75. Centers for Disease Control and Prevention. COVID-19. People with Certain Medical Conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Updated February 25, 2022.

76. World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Accessed April 8, 2022. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_18February2022.pdf. Published February 18, 2022.